<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926652</url>
  </required_header>
  <id_info>
    <org_study_id>SP-AC-001</org_study_id>
    <nct_id>NCT01926652</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg</brief_title>
  <official_title>An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the pharmacokinetic interactions and safety between single dose of
      amlodipine 10mg and candesartan 32mg and the combination dose amlodipine 10mg with
      candesartan 32mg in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC, Cmax</measure>
    <time_frame>7days, 10days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin, tmax, CL/F</measure>
    <time_frame>7days, 10days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan cilexetil 32mg, amlodipine 10mg</intervention_name>
    <description>Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.</description>
    <arm_group_label>candesartan</arm_group_label>
    <arm_group_label>amlodipine</arm_group_label>
    <other_name>atacand 32mg, norvasc 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male volunteers in the age between 20 and 55 years old(inclusive).

          2. Body weight &gt;= 55kg and Body mass index (BMI) in the range of calculated IBW ±20%.

          3. Subjects without a hereditary problems or chronic desease.

          4. Subjects whose clinical laboratory test values are inside the accepted normal range.

          5. Understand the requirements of the study and voluntarily consent to participate in the
             study.

        Exclusion Criteria:

          1. Subjects with a history of gastrointestinal diseases which might significantly change
             ADME of medicines.

          2. Systolic blood pressure range ≥150 mmHg or ≤ 100 mmHg or diastolic blood pressure
             range ≥ 95 mmHg or ≤ 60 mmHg.

          3. Subject with symptoms of acute disease within 14days prior to study medication dosing.

          4. Subjects with a history of clinically significant allergies of amlodipin or
             candesartan or CCB or other medicine (ex. aspirin or antibiotics).

          5. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption.

          6. Serum creatinine &gt; 1.2mg/dL.

          7. smoking &gt; 10 cigarettes/day.

          8. alcohol &gt; 210g/week.

          9. Positive test results for drug test in urin or subject with history of substance
             abuse.

         10. Participation in any clinical investigation within 2 months prior to study medication
             dosing.

         11. Subjects with whole blood donation within 2 months, component blood donation within 1
             month and blood transfusion within 1 month prior to study medication dosing.

         12. Subjects considered as unsuitable based on medical judgement by investigators.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungnam national university hospital, clinical trial center</name>
      <address>
        <city>Daejeon</city>
        <state>Chungcheongbul-do</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

